Highlights
Urolithin A (UA; Mitopure) administered orally for 4 months to middle‑aged, overweight, sedentary adults was safe and associated with: 1) significant improvements in lower‑limb (hamstring) strength (+12% with 500 mg, +9.8% with 1,000 mg versus placebo), 2) clinically meaningful increases in aerobic capacity and walking distance with the 1,000 mg dose (peak VO2 up ~10% within‑group; 6‑minute walk distance +33.4 m), and 3) muscle proteomic and biochemical signatures consistent with activation of Parkin‑mediated mitophagy and elevated mitochondrial OXPHOS proteins, together with reduced systemic CRP and selected inflammatory cytokines.
Specialty calculators
For clinical reference; use professional judgment.
